Financial Statement, January – December 2014
Financial summaries for the fourth quarter and the year as a whole*October to December 2014 (2013) · Net turnover totalled SEK 377.0 million (SEK 147.1 m), SEK 220.1 million (SEK 10.5 m) of which comprised royalties for simeprevir. · Revenues from Medivir’s own pharmaceutical sales totalled SEK 156.6 million (SEK 47.6 m), SEK 103.1 million (SEK 0) of which derived from sales of OLYSIO® and SEK 53.5 million (SEK 47.6 m) from sales of other pharmaceuticals. · The profit/loss after tax was SEK 147.3 million (SEK 19.3 m). · Basic and diluted earnings per share totalled SEK 4.71 (